Journal Watch · Frontiers in Immunology · 2026

CXCL1-CXCR2 axis inhibits melanogenesis through the suppression of the WNT/β-catenin pathway.

It provides novel perspectives for deciphering the pathogenesis of pigmentary skin disorders and developing therapeutic strategies with combined anti-inflammatory and depigmenting effects.

Zhang Y, Zhang F, Yu X et al.Frontiers in Immunology3 min readPharma relevance 50/100

DOI: 10.3389/fimmu.2026.1907373PMID: 42601941Study type: review / perspective

TL;DR

It provides novel perspectives for deciphering the pathogenesis of pigmentary skin disorders and developing therapeutic strategies with combined anti-inflammatory and depigmenting effects.

Key findings

  • Notably, CXCL1 treatment significantly decreased both the expression level and nuclear translocation of β-catenin, a key effector molecule of the WNT signaling pathway, and this effect was effectively reversed by the specific CXCR2 inhibitor SB225002, suggesting that the CXCL1-CXCR2 axis negatively regulates melanogenesis by suppressing the WNT/β-catenin signaling pathway.
  • In summary, this study elucidates a preliminary mechanism by which the CXCL1-CXCR2 axis negatively regulates melanogenesis through inhibition of the WNT/β-catenin signaling pathway, linking inflammatory cytokine networks to the regulatory machinery of melanogenesis.
  • It provides novel perspectives for deciphering the pathogenesis of pigmentary skin disorders and developing therapeutic strategies with combined anti-inflammatory and depigmenting effects.

What they did

To validate this finding, we exogenously treated human primary melanocytes, MNT1 cells, and ex vivo human foreskin tissues with CXCL1. The results showed that CXCL1 reduced melanin content, tyrosinase activity, and the expression of key melanogenesis-related genes, including MITF, TYR, TYRP1, and DCT. Mechanistic studies revealed that CXCL1 exerts these inhibitory effects through its canonical receptor CXCR2.

Full abstract (original)

Background: Abnormal skin pigmentation is a common clinical dermatological issue, and its occurrence and development are closely associated with the inflammatory microenvironment. However, the interactive regulatory mechanisms between inflammatory factors and melanogenesis remain incompletely understood. In this study, through the analysis of transcriptomic data from melasma, psoriasis, acne, atopic dermatitis, and ultraviolet-irradiated skin tissues, we found that CXCL1 may negatively regulate melanogenesis.

What they did: To validate this finding, we exogenously treated human primary melanocytes, MNT1 cells, and ex vivo human foreskin tissues with CXCL1. The results showed that CXCL1 reduced melanin content, tyrosinase activity, and the expression of key melanogenesis-related genes, including MITF, TYR, TYRP1, and DCT. Mechanistic studies revealed that CXCL1 exerts these inhibitory effects through its canonical receptor CXCR2.

Results & conclusions: Notably, CXCL1 treatment significantly decreased both the expression level and nuclear translocation of β-catenin, a key effector molecule of the WNT signaling pathway, and this effect was effectively reversed by the specific CXCR2 inhibitor SB225002, suggesting that the CXCL1-CXCR2 axis negatively regulates melanogenesis by suppressing the WNT/β-catenin signaling pathway. In summary, this study elucidates a preliminary mechanism by which the CXCL1-CXCR2 axis negatively regulates melanogenesis through inhibition of the WNT/β-catenin signaling pathway, linking inflammatory cytokine networks to the regulatory machinery of melanogenesis. It provides novel perspectives for deciphering the pathogenesis of pigmentary skin disorders and developing therapeutic strategies with combined anti-inflammatory and depigmenting effects.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1907373 · PubMed 42601941.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

It provides novel perspectives for deciphering the pathogenesis of pigmentary skin disorders and developing therapeutic strategies with combined anti-inflammatory and depigmenting effects.

What type of study is this?

It is a review / perspective, published in Frontiers in Immunology in 2026. To validate this finding, we exogenously treated human primary melanocytes, MNT1 cells, and ex vivo human foreskin tissues with CXCL1.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1907373. PubMed ID: 42601941. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Zhang Y, Zhang F, Yu X et al.. CXCL1-CXCR2 axis inhibits melanogenesis through the suppression of the WNT/β-catenin pathway.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1907373.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/cxcl1-cxcr2-axis-inhibits-melanogenesis-through-the-suppression-of-the-w-907373/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides